Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003229 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal
A Phase 1 study of Melanoma (Skin), sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
NCT00003229: Completed Phase 1 study of Melanoma (Skin), sponsored by Duke University.
NCT00003229 is a Phase 1 study of Melanoma (Skin) that has completed, run by Duke University. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003229, a Phase 1 study of Melanoma (Skin), has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill the tumor cells. PURPOSE: Randomized phase I/II trial to study the effectiveness of vaccine therapy made from white blood cells and melanoma cells in treating patients with metastatic melanoma who are undergoing surgery for lymph node and tumor removal.
Conditions Studied
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL gp100 antigen
- BIOLOGICAL tyrosinase peptide
Study Locations (2)
North Carolina
- Duke Comprehensive Cancer Center - Durham
Virginia
- Cancer Center, University of Virginia HSC - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-07 |
| Est. Completion | 2005-02 |
| Phase | Phase 1 |
What the finished NCT00003229 record still lists
NCT00003229 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 3 interventions - of which aldesleukin is the first listed.
NCT00003229 reports a single indexed study location in North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT00003229 about?
NCT00003229 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal". RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill the tumor cells. PURPOSE: Randomized phase I/II trial to study the effectiveness of vaccine therapy made from white blood cells and melanoma cells in treating patients w...
What is the current status of trial NCT00003229?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-07. Estimated completion is 2005-02.
What conditions does trial NCT00003229 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00003229?
The interventions under investigation include: aldesleukin (BIOLOGICAL), gp100 antigen (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003229?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003229 being conducted?
This trial has 2 study locations across North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia